ALS Breakthrough Pinpoints Common Weakness
New Research Identifies UNC13A Gene as Key Target for Treatment
Scientists have uncovered a unifying molecular mechanism in Amyotrophic Lateral Sclerosis (ALS), a devastating neurodegenerative disease. This discovery centers on the gene UNC13A, crucial for nerve cell communication, offering a promising new avenue for developing effective therapies.
Unraveling ALS Complexity
For years, the genetic diversity of ALS has complicated the search for a single effective treatment. Different genetic mutations, such as those affecting TDP-43, FUS, MATR3, and hnRNPA1, lead to varied pathological pathways. This heterogeneity makes it challenging to find a common therapeutic target.
“Scientists still don’t fully understand the process behind the loss of motor neurons in ALS. ALS is known for its genetic heterogeneity – meaning that there are numerous possible combinations of genes and factors that could lead to ALS. This makes it difficult to develop a singular treatment that works for everyone.”
—Yasuaki Watanabe, Assistant Professor, Tohoku University
A research team from Tohoku University and Keio University aimed to bridge this gap. They generated neural cell lines where key ALS-related RNA-binding proteins were depleted. Consistently, they observed a significant reduction in UNC13A expression across all tested cell lines.
Two Paths to UNC13A Deficiency
The study identified two distinct molecular routes leading to lower UNC13A levels. One pathway involves the insertion of a cryptic exon into the UNC13A transcript, destabilizing the messenger RNA. The second, novel finding revealed that the loss of FUS, MATR3, or hnRNPA1 triggers the overexpression of REST, a known transcriptional repressor.
REST actively suppresses UNC13A gene transcription. This increased REST activity may be the underlying cause of the motor neuron damage seen in ALS patients. The researchers validated these findings by examining motor neurons from ALS patient iPS cells and post-mortem spinal cord tissues, confirming elevated REST levels.
UNC13A: A Central Hub for Therapy
This convergence of diverse ALS-causing mutations on UNC13A deficiency provides critical insights into the disease. It highlights UNC13A as a central player in ALS pathology. Strategies aimed at preserving UNC13A expression or modulating REST activity could offer broad-spectrum therapeutic benefits.
“This study provides a valuable framework for developing broad-spectrum treatments that target shared molecular vulnerabilities in ALS,” stated **Keiko Nakayama**, Professor at Tohoku University.
With an estimated 30,000 people living with ALS in the United States alone, the potential to slow or halt the progression of muscle wasting and loss of function in a wider patient population would represent a monumental advancement in patient care (ALS Association).
